Rigel Pharmaceuticals(NASDAQ) RIGL

Rigel Pharmaceuticals, Inc. creates medicines for patients with rare blood disorders and cancer. These treatments help people whose immune systems destroy their own blood cells. The company provides new therapy options when standard medical treatments fail.

Medicines for Blood and Cancer

• TAVALISSE: Oral pill for adult patients with chronic immune thrombocytopenia; generated $84.7 million in net product sales for the six-month period ended June 30, 2026.
• REZLIDHIA: Monotherapy for adults with specific mutated forms of relapsed or refractory acute myeloid leukemia; accounted for $17.0 million in net product sales for the first half of 2026.
• GAVRETO: Daily oral treatment for metastatic lung and thyroid cancers with specific genetic fusions; produced $20.3 million in net product sales for the six-month period ended June 30, 2026.
• VEPPANU: First oral protein degrader approved for certain types of advanced breast cancer; expected to launch commercially in mid-August 2026.
• Pipeline Candidates: Investigational programs like R289 for lower-risk myelodysplastic syndrome currently in Phase 1b clinical trials.

New Drugs and Key Partnerships

• Acquired US rights to GAVRETO from Blueprint Medicines in February 2024 to strengthen its oncology portfolio.
• In-licensed VEPPANU from Arvinas and Pfizer in May 2026 to expand into breast cancer treatment.
• Established a strategic development alliance with MD Anderson Cancer Center for leukemia research in December 2023.
• Collaborated with the Collaborative Network for Neuro-Oncology Clinical Trial to study brain tumor treatments in January 2024.

Reaching Patients with Specialized Care

Rigel uses specialized technology to target signaling pathways that drive disease growth. Its commercial team provides patient support through the Rigel OneCare program to help with costs and insurance coverage.

Rigel by the Numbers

• Net product sales reached $121.9 million for the six months ended June 30, 2026, up 19% year over year.
• TAVALISSE net product sales rose to $84.7 million for the first half of 2026, a 24% increase year over year.
• Research and development expenses grew to $25.6 million for the six-month period ended June 30, 2026.
• The company held $95.3 million in cash, cash equivalents, and short-term investments as of June 30, 2026.

A Growing Portfolio

Rigel has transitioned from a research group into a commercial company with four approved treatments. Its focus on niche cancers and strategic drug acquisitions supports its expansion in the biotechnology sector.